AR110003A2 - Derivado de amida - Google Patents
Derivado de amidaInfo
- Publication number
- AR110003A2 AR110003A2 ARP170103011A ARP170103011A AR110003A2 AR 110003 A2 AR110003 A2 AR 110003A2 AR P170103011 A ARP170103011 A AR P170103011A AR P170103011 A ARP170103011 A AR P170103011A AR 110003 A2 AR110003 A2 AR 110003A2
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- group
- substituted
- alkoxy
- aryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Reivindicación 1: Un derivado de amida de fórmula (1), o una sal farmacéuticamente aceptable del mismo, caracterizado porque: A es un resto de fórmula (2) ó (3) siendo R⁴, R⁵, R⁶ y R⁷ cada uno independientemente hidrógeno, halógeno, N-alquilo C₁₋₆ o N-hidroxi amido o C-alquilo C₁₋₆ amido inverso (-NHCOC₁₋₆), hidroxicarbonilo (-COOH), alquiloxicarbonilo C₁₋₆ (-COOC₁₋₆), alquilo C₁₋₆, o alquilo C₁₋₆ substituido con un grupo hidroxi, dialquilamina C₁₋₆ o grupo heterocíclico; R¹ es un grupo arilo o heterocíclico substituido con uno a cinco X, o alquilo C₁₋₆ substituido con arilo; R² es hidrógeno, hidroxi, alcoxi C₁₋₆, o alcoxi C₁₋₆ substituido con un grupo alcoxi C₁₋₆ o heterocíclico; R³ es hidrógeno, -COOH, alquiloxicarbonilo C₁₋₆, o amido N-no substituido o N-substituido con Y; nₐ y nᵇ son cada uno un entero que oscila entre 0 y 6; en donde: X es hidrógeno, halógeno, hidroxi, ciano, nitro, (mono-, di-, o trihalógeno)metilo, mercapto, alquiltio C₁₋₆, acrilamido, alquilo C₁₋₆, alquenilo C₁₋₆, alquinilo C₁₋₆, alcoxi C₁₋₆, ariloxi, dialquilamino C₁₋₆, o alquilo C₁₋₆ o alcoxi C₁₋₆ substituido con Z, con la condiciona de que cuando el número de X es dos o más, los grupos X pueden fusionarse entre sí para formar una estructura de anillo; Y es hidroxi, alquilo C₁₋₆ o alquilo C₁₋₆ substituido con Z, conteniendo el alquilo C₁₋₆ una a cuatro de la parte seleccionada entre el grupo que consiste en N, O, S, SO y SO₂; y Z es un grupo alquilo C₁₋₆, arilo o heterocíclico, siendo dicho grupo arilo un grupo aromático monocíclico o bicíclico C₅₋₁₂, siendo dicho grupo heterocíclico un grupo aromático o no aromático monocíclico o bicíclico C₅₋₁₂ que contiene una a cuatro de la parte seleccionada entre el grupo que consiste en N, O, S, SO y SO₂ y siendo dichos grupos arilo y heterocíclico no substituidos o substituidos con substituyente seleccionados entre el grupo que consiste en halógeno, hidroxilo, amino, nitro, ciano, alquilo C₁₋₆, alquenilo C₁₋₆, alquinilo C₁₋₆, alcoxi C₁₋₆, monoalquilamino C₁₋₆ y dialquilamino C₁₋₆.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20070054997 | 2007-06-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR110003A2 true AR110003A2 (es) | 2019-02-13 |
Family
ID=40094307
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080102395A AR066876A1 (es) | 2007-06-05 | 2008-06-05 | Derivados de amida para inhibir el crecimiento de celulas cancerigenas y una composicion farmaceutica que los comprende. |
| ARP170103011A AR110003A2 (es) | 2007-06-05 | 2017-10-30 | Derivado de amida |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080102395A AR066876A1 (es) | 2007-06-05 | 2008-06-05 | Derivados de amida para inhibir el crecimiento de celulas cancerigenas y una composicion farmaceutica que los comprende. |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US8188102B2 (es) |
| EP (1) | EP2167492B1 (es) |
| JP (1) | JP5155391B2 (es) |
| KR (1) | KR101013319B1 (es) |
| CN (1) | CN101679384B (es) |
| AR (2) | AR066876A1 (es) |
| AU (1) | AU2008260772B2 (es) |
| BR (1) | BRPI0811069B1 (es) |
| CA (1) | CA2687180C (es) |
| DK (1) | DK2167492T3 (es) |
| ES (1) | ES2558623T3 (es) |
| HK (1) | HK1142591A1 (es) |
| HR (1) | HRP20160007T1 (es) |
| HU (1) | HUE028243T2 (es) |
| IL (1) | IL202154A (es) |
| MX (1) | MX2009012772A (es) |
| MY (1) | MY144972A (es) |
| NZ (1) | NZ582412A (es) |
| PL (1) | PL2167492T3 (es) |
| PT (1) | PT2167492E (es) |
| RU (1) | RU2434010C2 (es) |
| TW (1) | TWI377944B (es) |
| UA (1) | UA96045C2 (es) |
| WO (1) | WO2008150118A2 (es) |
| ZA (1) | ZA201000022B (es) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7547781B2 (en) | 2006-09-11 | 2009-06-16 | Curis, Inc. | Quinazoline based EGFR inhibitors containing a zinc binding moiety |
| SG174774A1 (en) | 2006-09-11 | 2011-10-28 | Curis Inc | Quinazoline based egfr inhibitors containing a zinc binding moiety |
| US8119616B2 (en) | 2007-09-10 | 2012-02-21 | Curis, Inc. | Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety |
| WO2010129053A2 (en) | 2009-05-05 | 2010-11-11 | Dana Farber Cancer Institute | Egfr inhibitors and methods of treating disorders |
| KR101217526B1 (ko) * | 2010-06-11 | 2013-01-02 | 한미사이언스 주식회사 | 아마이드 유도체 또는 이의 약학적으로 허용 가능한 염을 포함하는 약제학적 조성물 |
| US8828391B2 (en) | 2011-05-17 | 2014-09-09 | Boehringer Ingelheim International Gmbh | Method for EGFR directed combination treatment of non-small cell lung cancer |
| KR101317809B1 (ko) * | 2011-06-07 | 2013-10-16 | 한미약품 주식회사 | 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물 |
| KR101272613B1 (ko) * | 2011-10-05 | 2013-06-10 | 한미사이언스 주식회사 | 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온 염산염의 제조 방법 및 이에 사용되는 중간체 |
| US9586965B2 (en) | 2012-01-13 | 2017-03-07 | Acea Biosciences Inc. | Pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases |
| US9034885B2 (en) | 2012-01-13 | 2015-05-19 | Acea Biosciences Inc. | EGFR modulators and uses thereof |
| EP2802568A1 (en) | 2012-01-13 | 2014-11-19 | Acea Biosciences, Inc. | Heterocyclic compounds and uses as anticancer agents. |
| US9464089B2 (en) | 2012-01-13 | 2016-10-11 | Acea Biosciences Inc. | Heterocyclic compounds and uses thereof |
| UA111010C2 (uk) | 2012-01-17 | 2016-03-10 | Астеллас Фарма Інк. | Сполука піразинкарбоксаміду |
| CN102659764A (zh) * | 2012-04-16 | 2012-09-12 | 中国科学院广州生物医药与健康研究院 | 酪氨酸激酶不可逆抑制剂及其制备方法和用途 |
| KR20140096571A (ko) | 2013-01-28 | 2014-08-06 | 한미약품 주식회사 | 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법 |
| CN105916851A (zh) | 2013-07-11 | 2016-08-31 | 艾森生物科学公司 | 嘧啶衍生物作为激酶抑制剂 |
| CN104513229A (zh) * | 2013-09-28 | 2015-04-15 | 正大天晴药业集团股份有限公司 | 喹唑啉衍生物及其制备方法 |
| CN106068262B (zh) * | 2014-04-11 | 2019-10-29 | 海思科医药集团股份有限公司 | 喹唑啉衍生物及其制备方法和在医药上的应用 |
| WO2016090174A1 (en) * | 2014-12-03 | 2016-06-09 | Auckland Uniservices, Ltd. | Kinase inhibitor prodrug for the treatment of cancer |
| CN107406430B (zh) * | 2015-03-20 | 2019-04-26 | 正大天晴药业集团股份有限公司 | 喹唑啉衍生物的盐及其制备方法 |
| CA3001744A1 (en) | 2015-10-09 | 2017-04-13 | ACEA Therapeutics, Inc. | Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same |
| WO2018036539A1 (zh) * | 2016-08-25 | 2018-03-01 | 正大天晴药业集团股份有限公司 | 喹唑啉衍生物的盐的晶体 |
| CN108069946B (zh) * | 2016-11-08 | 2020-06-05 | 威尚（上海）生物医药有限公司 | 具有穿过血脑屏障能力的取代的喹唑啉化合物 |
| US10898487B2 (en) | 2016-12-22 | 2021-01-26 | Boehringer Ingelheim International Gmbh | Benzylamino substituted quinazolines and derivatives as SOS1 inhibitors |
| TWI808958B (zh) | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | 涉及二芳基巨環化合物之組合療法 |
| WO2018157813A1 (zh) | 2017-02-28 | 2018-09-07 | 南京明德新药研发股份有限公司 | 螺环类化合物及其应用 |
| CA3059072A1 (en) | 2017-04-07 | 2018-10-11 | ACEA Therapeutics, Inc. | Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same |
| BR112019022229A2 (pt) * | 2017-04-27 | 2020-05-12 | Astrazeneca Ab | Compostos de anilinoquinazolina c5 e seu uso no tratamento do câncer |
| AR113451A1 (es) * | 2017-10-18 | 2020-05-06 | Spectrum Pharmaceuticals Inc | Inhibidores de tirosina quinasas de la familia de los egfr mutantes |
| US20210078958A1 (en) * | 2017-12-19 | 2021-03-18 | Medshine Discovery Inc. | Quinazoline derivative and use thereof |
| TWI810230B (zh) | 2017-12-21 | 2023-08-01 | 德商百靈佳殷格翰國際股份有限公司 | 作為sos1抑制劑之新穎芐胺基取代吡啶并嘧啶酮及衍生物 |
| EP3773551A4 (en) * | 2018-03-27 | 2022-03-23 | Board of Regents, The University of Texas System | COMPOUNDS WITH ANTITUMOR ACTIVITY AGAINST CANCER CELLS CARRYING HER2 EXON 19 MUTATIONS |
| WO2019223671A1 (zh) * | 2018-05-24 | 2019-11-28 | 深圳市塔吉瑞生物医药有限公司 | 取代的氨基喹唑啉类化合物及其药物组合物及其用途 |
| WO2019233459A1 (zh) * | 2018-06-08 | 2019-12-12 | 江苏威凯尔医药科技有限公司 | 人表皮生长因子受体抑制剂及其制备方法和应用 |
| CN110577514B (zh) * | 2018-06-08 | 2022-07-05 | 江苏威凯尔医药科技有限公司 | 人表皮生长因子受体抑制剂及其制备方法和应用 |
| CN108623490A (zh) * | 2018-06-22 | 2018-10-09 | 苏州市贝克生物科技有限公司 | (2z)-4-(二甲基氨基)-2-丁烯酸盐酸盐的合成方法 |
| EP3810644A4 (en) | 2018-06-25 | 2022-03-23 | Spectrum Pharmaceuticals, Inc. | COMBINATION OF POZIOTINIB WITH A CYTOTOXIC AGENT AND/OR OTHER MOLECULAR TARGETING AGENT AND USE THEREOF |
| TW202012391A (zh) * | 2018-07-04 | 2020-04-01 | 日商第一三共股份有限公司 | 二芳基醚型喹唑啉衍生物 |
| BR112021004527A2 (pt) * | 2018-09-14 | 2021-06-08 | Spectrum Pharmaceuticals, Inc. | kits e métodos para tratamento contra câncer |
| WO2020061470A1 (en) * | 2018-09-21 | 2020-03-26 | Spectrum Pharmaceuticals, Inc. | Novel quinazoline egfr inhibitors |
| EP3856726A1 (en) | 2018-09-25 | 2021-08-04 | Black Diamond Therapeutics, Inc. | Quinazoline derivatives as tyrosine kinase inhibitor, compositions, methods of making them and their use |
| KR101950942B1 (ko) | 2019-01-28 | 2019-02-22 | 한미약품 주식회사 | 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법 |
| CN115838369A (zh) | 2019-03-19 | 2023-03-24 | 株式会社沃若诺伊 | 杂芳基衍生物、其制备方法、及含其作为有效成分的药物组合物 |
| AU2020261423A1 (en) | 2019-04-25 | 2021-12-09 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of tyrosine kinase |
| EP3966315A1 (en) | 2019-05-09 | 2022-03-16 | FUJIFILM Cellular Dynamics, Inc. | Methods for the production of hepatocytes |
| CN114144418B (zh) * | 2019-06-19 | 2023-10-10 | 成都金瑞基业生物科技有限公司 | 喹唑啉类化合物的晶型、盐型及其制备方法 |
| WO2020262998A1 (ko) * | 2019-06-26 | 2020-12-30 | 한미약품 주식회사 | 항 종양 활성을 갖는 신규 퀴나졸린 유도체 및 이를 포함하는 약학 조성물 |
| KR20210049004A (ko) | 2019-10-24 | 2021-05-04 | 한미약품 주식회사 | 암세포의 성장을 억제하는 아마이드 유도체를 포함하는 약제학적 제제 및 이를 포함하는 약제학적 제품 |
| WO2021127397A1 (en) * | 2019-12-19 | 2021-06-24 | Black Diamond Therapeutics, Inc. | Nitrogen heterocyclic compounds and methods of use |
| CA3166298A1 (en) * | 2020-01-29 | 2021-08-05 | John Heymach | Use of quinazoline-based tyrosine kinase inhibitors for the treatment of cancers with nrg1 fusions |
| WO2021231400A1 (en) * | 2020-05-12 | 2021-11-18 | Accutar Biotechnology, Inc. | Bis-aryl ethers containing n-acyl azetidine as egfr/her2 inhibitors |
| CN111763215B (zh) * | 2020-07-21 | 2021-05-18 | 成都海博为药业有限公司 | 一种具有含氮杂环结构的化合物及其制备方法和用途 |
| WO2022105908A1 (zh) * | 2020-11-23 | 2022-05-27 | 上海和誉生物医药科技有限公司 | Egfr抑制剂及其制备方法与在药学上的应用 |
| WO2022170043A1 (en) * | 2021-02-05 | 2022-08-11 | Accutar Biotechnology, Inc. | Quinazoline derived compounds as egfr inhibitors and their uses thereof |
| JP2024523861A (ja) | 2021-06-15 | 2024-07-02 | ジェネンテック， インコーポレイテッド | がんを処置するための併用療法におけるｅｇｆｒ阻害剤およびｐｅｒｋ活性化剤、ならびにこれらの使用 |
| WO2022266426A1 (en) * | 2021-06-17 | 2022-12-22 | Black Diamond Therapeutics, Inc. | 6-(heterocycloalkyl-oxy)-quinazoline derivatives and uses thereof |
| WO2022266427A1 (en) * | 2021-06-17 | 2022-12-22 | Black Diamond Therapeutics, Inc. | 4-(aryl-methyl-amino)-quinazoline derivatives and uses thereof |
| KR20240069728A (ko) * | 2021-08-24 | 2024-05-20 | 아쓰로시 테라퓨틱스, 인크. | 질환의 치료를 위한 퀴나졸린 화합물 |
| CN115894486B (zh) * | 2021-09-30 | 2024-02-09 | 北京赛特明强医药科技有限公司 | 一种氢化吡啶并喹唑啉类化合物、组合物及其应用 |
| WO2023128350A1 (ko) * | 2021-12-30 | 2023-07-06 | 주식회사 비투에스바이오 | 헤테로아릴 유도체 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 |
| WO2024083120A1 (zh) * | 2022-10-18 | 2024-04-25 | 南京明德新药研发有限公司 | 苄氨基喹啉类化合物及其制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI324597B (en) * | 2002-03-28 | 2010-05-11 | Astrazeneca Ab | Quinazoline derivatives |
| JP4776882B2 (ja) | 2002-03-30 | 2011-09-21 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | 二環式複素環化合物、これらの化合物を含む医薬組成物、それらの使用及びそれらの調製方法 |
| GB0309009D0 (en) * | 2003-04-22 | 2003-05-28 | Astrazeneca Ab | Quinazoline derivatives |
| UY28441A1 (es) * | 2003-07-29 | 2005-02-28 | Astrazeneca Ab | Derivados de quinazolina |
| WO2005026151A1 (en) * | 2003-09-16 | 2005-03-24 | Astrazeneca Ab | Quinazoline derivatives as tyrosine kinase inhibitors |
| GB0322409D0 (en) * | 2003-09-25 | 2003-10-29 | Astrazeneca Ab | Quinazoline derivatives |
| JP2007506716A (ja) * | 2003-09-25 | 2007-03-22 | アストラゼネカ アクチボラグ | キナゾリン誘導体 |
| EP1734040A4 (en) * | 2004-03-23 | 2007-11-28 | Banyu Pharma Co Ltd | SUBSTITUTED CHINAZOLINE OR PYRIDOPYRIMIDINE DERIVATIVE |
| US20100234371A1 (en) * | 2005-08-22 | 2010-09-16 | Frank Himmelsbach | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof |
| WO2007055513A1 (en) * | 2005-11-08 | 2007-05-18 | Hanmi Pharm. Co., Ltd. | Quinazoline derivatives as a signal transduction inhibitor and method for the preparation thereof |
-
2008
- 2008-06-04 TW TW097120707A patent/TWI377944B/zh active
- 2008-06-05 WO PCT/KR2008/003162 patent/WO2008150118A2/en active Application Filing
- 2008-06-05 UA UAA200913594A patent/UA96045C2/ru unknown
- 2008-06-05 CA CA2687180A patent/CA2687180C/en active Active
- 2008-06-05 CN CN2008800188259A patent/CN101679384B/zh active Active
- 2008-06-05 EP EP08766124.5A patent/EP2167492B1/en active Active
- 2008-06-05 RU RU2009149307/04A patent/RU2434010C2/ru active
- 2008-06-05 NZ NZ582412A patent/NZ582412A/en unknown
- 2008-06-05 PT PT87661245T patent/PT2167492E/pt unknown
- 2008-06-05 US US12/663,263 patent/US8188102B2/en active Active
- 2008-06-05 BR BRPI0811069-7A patent/BRPI0811069B1/pt active IP Right Grant
- 2008-06-05 MY MYPI20094841A patent/MY144972A/en unknown
- 2008-06-05 HU HUE08766124A patent/HUE028243T2/en unknown
- 2008-06-05 AR ARP080102395A patent/AR066876A1/es active IP Right Grant
- 2008-06-05 ES ES08766124.5T patent/ES2558623T3/es active Active
- 2008-06-05 JP JP2010511117A patent/JP5155391B2/ja active Active
- 2008-06-05 AU AU2008260772A patent/AU2008260772B2/en active Active
- 2008-06-05 PL PL08766124T patent/PL2167492T3/pl unknown
- 2008-06-05 KR KR1020080052867A patent/KR101013319B1/ko active IP Right Grant
- 2008-06-05 DK DK08766124.5T patent/DK2167492T3/en active
- 2008-06-05 MX MX2009012772A patent/MX2009012772A/es active IP Right Grant
-
2009
- 2009-11-16 IL IL202154A patent/IL202154A/en active IP Right Grant
-
2010
- 2010-01-04 ZA ZA2010/00022A patent/ZA201000022B/en unknown
- 2010-09-20 HK HK10108928.8A patent/HK1142591A1/xx unknown
-
2016
- 2016-01-05 HR HRP20160007TT patent/HRP20160007T1/hr unknown
-
2017
- 2017-10-30 AR ARP170103011A patent/AR110003A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR110003A2 (es) | Derivado de amida | |
| AR055592A1 (es) | Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace) | |
| ECSP12011838A (es) | Derivados de la cromenona con actividad anti-tumoral | |
| NI201900029A (es) | COMPUESTOS DE BENZO[b]TIOFENO COMO AGONISTAS DE STING | |
| PE20190326A1 (es) | Isoquinolin-3-il-carboxamidas y preparacion y uso de las mismas | |
| AR070193A1 (es) | Terapia combinada que comprende inhibidores de sglt e inhibidores de dpp4, composicion farmaceutica y uso | |
| AR076228A1 (es) | Piperidinas sustituidas como antagonistas de ccr3 | |
| AR092522A1 (es) | Inhibidores de glucosilceramida sintasa | |
| PE20090648A1 (es) | Compuestos para el tratamiento de la hepatitis c | |
| CO5700752A2 (es) | Derivados de piperazina y piperazin-2-ona especificos al receptor de melano cortina | |
| CO6341631A2 (es) | Derivados de 1,2,4 - oxadiazol y su uso terapéutico | |
| ECSP099371A (es) | INHIBIDORES ESPIRO CETONA DE ACETIL-CoA CARBOXILASA | |
| AR119010A1 (es) | Compuestos, composiciones y métodos de uso | |
| AR078151A1 (es) | Conjugados de acidos grasos y niacina, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades metabolicas. | |
| AR107927A1 (es) | Compuestos de pirrolidina, sal farmacéuticamente aceptable del mismo, composición farmacéutica que lo comprende y su uso para la fabricación de un medicamento | |
| AR090572A1 (es) | Derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos | |
| AR066103A1 (es) | Derivados de triazolopiridin - carboxamidas, su preparacion y su aplicacion en terapeutica | |
| AR065131A1 (es) | Derivados triciclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| AR060800A1 (es) | Derivados de aminometilpiridina su preparacion y su aplicacion en terapeutica | |
| AR051041A1 (es) | Bencimidazoles triciclicos condensados | |
| AR064866A1 (es) | Analogos de piridina | |
| AR054103A1 (es) | Sales de amino de 1,2,3-triazoles, composiciones farmaceuticas que las contienen y usos como agentes antivirales | |
| BR112013024957A2 (pt) | derviado de furanona ou um sal farmaceuticamente aceitável do mesmo | |
| AR057615A1 (es) | Derivados de isoquinolina y benzo (h) isoquinolina su preparcion y su utilizacion en terapeutica | |
| AR050447A1 (es) | Derivados de pirrol, su preparacion y su aplicacion en terapeutica. |